Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

BCL2 (B-cell leukemia/lymphoma 2) gene functions as antiapoptotic regulatory element and known to be associated with tumorigenesis. The SNP-938 (C>A) (rs2279115), located in the inhibitory P2 promoter of the BCL2 gene, influences differential binding affinities of transcriptional factors thereby affecting BCL2 expression. The present study is an attempt to evaluate the association between BCL2(-938C>A) polymorphism and clinical characteristics of breast cancer patients as well as to analyze BCL2 expression and Ki67 proliferation index with respect to the genotypes. One hundred ten primary breast cancer tumor tissues were genotyped for -938 C>A polymorphism through PCR-RFLP method as well as evaluated for BCL2 expression and ki67 proliferation index by immunohistochemistry. Evaluation of apoptosis level was performed by flowcytometry. The results revealed that AA genotype was associated with an increased risk (AA Vs AC + CC) by 2.86-fold (p = 0.07) for breast cancer development which reflected in elevated A allele frequency also. AA genotype was found to be predominant among BCL2 positive tumors as compared to BCL2 negative tumors. Further, AA genotype was found to be associated with advanced stage tumors, node positive status, and high Ki67 proliferation index compared to CA and CC genotypes indicating that elevated expression of BCL2 gene in the presence of A allele might be associated with decreased apoptosis and enhanced proliferation rate. AA genotype of BCL2-938C>A polymorphism might influence BCL2 gene expression there by associated with elevated risk for breast cancer progression. Probably, failure of apoptosis due to enhanced expression and antiapoptotic protein BCL2 might promote malignant growth.
Literature
1.
Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocyticleukemia (CLL). Leukemia. 2002;16(6):1045–52.CrossRefPubMed
2.
Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110(4):443–9.CrossRefPubMed
3.
Ofner D, Riehemann K, Maier H, et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer. 1995;72:981–98.CrossRefPubMedPubMedCentral
4.
Silvestrini R, Benini E, Veneroni S, Daidone MG, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol. 1996;14(5):1604–10.CrossRefPubMed
5.
Seto M, Jaeger U, et al. Alternative promoter and exons, somatic mutation and deregulation of the Bcl-2 Ig fusion gene in lymphoma. EMBO J. 1988;7(1):123–31.PubMedPubMedCentral
6.
Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13(6):3686–97.CrossRefPubMedPubMedCentral
7.
Bachmann HS, Heukamp LC, et al. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer. 2011;129(10):2390–9.CrossRefPubMed
8.
Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P et al. Influence of BCL2 -938C > A and BAX-248G > A promoter polymorphisms in the development of AML: case-control study from South India. Tumor Biol. 2015;36(10): 7967–76.
9.
Li W, Qian C, et al. Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population. Tumor Biol. 2014;35:2259–64.CrossRef
10.
Lehnerdt GF, Franz P, Bankfalvi A, et al. The regulatory BCL2 promoter polymorphism (2938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009;20:1094–9.CrossRefPubMed
11.
Nuckel H, Frey UH et al. Association of a novel regulatory polymorphism (_938C_A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290–7.
12.
Bachmann HS, Otterbach F, Callies R, et al. The AA Genotype of the Regulatory BCL2 Promoter Polymorphism (-938C>A) Is Associated with a Favorable Outcome in Lymph Node-Negative Invasive Breast Cancer patients. Clin Cancer Res. 2007;13:5790–7.CrossRefPubMed
13.
Majid A, Tsoulakis O, Walewska R, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood. 2008;111(2):874–7.CrossRefPubMed
14.
Pikor LA, Enfield KS, Cameron H, Lam WL. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp. 2011;49:2763.
15.
Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol. 2010;23(2):251–9.CrossRefPubMed
16.
Kim OH, Jo HY, Lee J, Yoon SK. The C1772T genetic polymorphism in human HIF-1α gene associates with expression of HIF-1α protein in breast cancer. Oncol. Rep. 2008;20(5):1181–7.
17.
Meka PB, Cingeetham A, Nanchari SR, et al. HIF-1a (1772C>T) polymorphism as marker for breast cancer development. Tumor Biol. 2014;36:3215–20.CrossRef
18.
Simoes-Wust AP, Schurpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat. 2002;76(2):157–66.CrossRefPubMed
19.
Pepper C, Hooper K, et al. Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma. 2001;42(3):491–8.CrossRefPubMed
Metadata
Title
Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer
Publication date
01-05-2016
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4554-0

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Review

HSPB1 polymorphisms might be associated with radiation-induced damage risk in lung cancer patients treated with radiotherapy

Original Article

Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma

Original Article

Association between interleukin 8 −251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case–control study

Original Article

Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 CIP1/WAF1 expression

Original Article

13-Oxyingenol dodecanoate, a cytotoxic ingenol derivative, induces mitochondrial apoptosis and caspase-dependent Akt decrease in K562 cells

Original Article

Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits